Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy - sprookjes - yvandenbroek - TriplyDB

Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy

Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy

http://www.wikidata.org/entity/Q34973787

about

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease Tau Biology and Tau-Directed Therapies for Alzheimer's Disease Getting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrier Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology.Drug candidates in clinical trials for Alzheimer's disease.Antibody-derived in vivo imaging of tau pathology.Tau aggregation and its interplay with amyloid-β.Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies.Extracellular vesicles and their synthetic analogues in aging and age-associated brain diseases.A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.Detecting tau in serum of transgenic animal models after tau immunotherapy treatment.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Therapy and clinical trials in frontotemporal dementia: past, present, and future.Tau passive immunization inhibits not only tau but also Aβ pathology Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease.Active immunotherapy options for Alzheimer's disease.Harnessing the immune system for treatment and detection of tau pathology.Invited review: Drug development for tauopathies.Further understanding of tau phosphorylation: implications for therapy.Tau Immunotherapy.Developing therapeutic vaccines against Alzheimer's disease.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice.Immunotherapies for neurodegenerative diseases: current status and potential of plant-made biopharmaceuticals.First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.Emerging amyloid and tau targeting treatments for Alzheimer's disease.Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease.NPT088 reduces both amyloid-β and tau pathologies in transgenic mice Emerging Diagnostic and Therapeutic Strategies for Tauopathies.The past, present, and future of disease-modifying therapies for Alzheimer's disease.Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer's disease subjects: an exploratory study.Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy.Tauopathies: Mechanisms and Therapeutic Strategies.

P2860

Q26739412-A66D3140-DE3B-40EE-BA19-029CDF953CEE Q28071398-EFFC2AD7-D942-4C64-B957-3435CF0C0E12 Q28071873-C3C74B9A-35CE-4B29-9C1B-6B4C12C2265D Q28077869-1642013C-EFF2-431F-A3B6-41ACCD7E5480 Q33640390-D599955F-472E-4660-923F-DFCF82968A92 Q33865294-6AFE447D-F0E1-4CDF-B59F-81E1AE94701F Q33887379-DEDCE505-B228-4977-81CA-53674C672C80 Q33900736-A80E0DD5-2A95-4B71-87D4-B9990DE1D41A Q33916749-92F367F6-CDBF-499D-9AD9-16303AA19611 Q34664345-D0B43E89-3861-45AC-BC9E-FA5B103A3F32 Q35008256-D93AEB27-1BC2-4676-82FF-FB3E6BC0F5BC Q35204878-25D07E2D-0D5C-4F45-898A-D8254C564E0D Q35745135-501E809D-53A2-4ED7-BB98-E8F9178B6973 Q36081720-01FD6F7F-435F-4E26-AA06-64E45991660E Q36240389-4A94CCBC-2F3B-41A1-85EC-24ECE160A066 Q36395623-FF1F9859-BB6C-4DAF-91F1-67403E1174C9 Q36484413-0483B9C0-5A37-4F9F-B45E-FADA9BF37FE3 Q37566888-7A47CDEE-ECD8-4F10-A5AD-8EBCAD2BD5C2 Q37579019-C4EAC3A1-F33F-4DB1-BBDC-D355E60D9F2F Q37610545-B0150058-0486-464F-8D0A-BB92F7D9E42E Q38175453-85E4BB28-0C36-4AC6-B10F-B682C70D4E36 Q38183140-3B18952B-5093-4E53-8724-0779E969975D Q38194049-6E4AAF53-4C04-4994-8781-AEFEDF028567 Q38263698-21E5D801-BBF8-4091-A923-0CEB7AB059AD Q38306065-795CAD8B-AAE6-4179-B2DD-63932DB2286B Q38628672-B99091D1-5139-42C5-B22F-62948F344F85 Q38636151-46AC0C94-C6DB-4B45-8501-2357BC491880 Q38715233-E1E37F7C-506D-4319-97C0-C4CA264CC2FA Q38892738-897E3004-B4B6-4C6B-A464-A014B9BA74F1 Q38942195-7986C5BA-9D2D-4DAF-8500-F36F0EB7C102 Q39083050-3B5F739E-CD55-4B10-BA11-A9F5E40E2AC1 Q39296311-1B80FC6D-206D-4D25-A39B-8D06B6FEF3D2 Q41629521-9B7AE434-6C17-4945-89B2-B004EF2E83F2 Q42026368-C0F25727-648C-446E-90A1-B7E3AA2065FA Q42656183-5A3E334C-4DB7-40A3-B0F3-EC5668734084 Q45870549-302D2463-B9F5-4474-B90E-6354572B015F Q46244313-E0548D8E-CF8E-44F7-8003-86604CC43C81 Q47099501-8BCF4A90-DED7-4F04-8736-F0D1091C4E09 Q47222390-618E3201-AF9B-4987-99E4-249C6E9B6497 Q47253592-376F5D4E-8B0B-45C7-9E8C-F68EBFCAF3AF

P2860

Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy

http://www.wikidata.org/entity/Q34973787

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Efficacy and safety of a lipos ...... 301L mice that model tauopathy

@ast

Efficacy and safety of a lipos ...... 301L mice that model tauopathy

@en

Efficacy and safety of a lipos ...... 301L mice that model tauopathy

@nl

type

label

Efficacy and safety of a lipos ...... 301L mice that model tauopathy

@ast

Efficacy and safety of a lipos ...... 301L mice that model tauopathy

@en

Efficacy and safety of a lipos ...... 301L mice that model tauopathy

@nl

prefLabel

Efficacy and safety of a lipos ...... 301L mice that model tauopathy

@ast

Efficacy and safety of a lipos ...... 301L mice that model tauopathy

@en

Efficacy and safety of a lipos ...... 301L mice that model tauopathy

@nl

P1433

Q34973787-2EF46376-8C8C-40BE-A2FC-84F0B488441E

P1476

Q34973787-2038AE22-8E56-49D7-9B6B-00BEB0E7BDFF

P2093

Q34973787-1D5C74B4-2A36-4248-B8BD-935D158FE9E5

Q34973787-2562543F-197D-4F90-9ADD-A94498479F68

Q34973787-5C5C7C5B-AB61-4660-9D0C-37B2E3D7498E

Q34973787-696C54A7-C2BE-4247-BFCE-DC7E96147788

Q34973787-697B2487-D174-4299-B800-7E371F7DD3A0

Q34973787-8BA95FD0-8A72-4DAF-8D1D-B1F607B3F9B2

Q34973787-8EEAB1E8-799F-4016-B049-0EF74BFC737A

Q34973787-947D1982-FE9A-460E-9081-87431F51416F

Q34973787-A92EF4E9-BA24-4A5C-9F24-21E07A72D094

Q34973787-C14A83A3-CCBE-4E0F-A7BC-6F0EDA31C5AC

P2860

Q34973787-04995129-8503-4B73-908F-39E8D8C789A8

Q34973787-08B7BE63-A9F6-4EB7-92F9-0CE50C7EAE97

Q34973787-09191BE9-2873-4774-855E-FED7E046F4E7

Q34973787-128BBCBD-83AB-4B7A-AEC3-3528EDBEFD75

Q34973787-1311BF92-7E8C-467B-84B3-2D6CCF57B40D

Q34973787-1579336B-E650-454C-B8BF-92B3BEB448C5

Q34973787-1B994943-3B23-4E7A-9153-2452B54B89E0

Q34973787-1F93DDD5-8E9B-4ABA-9688-FB1C46346103

Q34973787-20A4514E-CFE7-4DD1-A469-DDD26ACE3687

Q34973787-22F5688F-80B7-4F29-B85F-794C3814B9F4

P304

Q34973787-134DFDCA-7565-4102-B0FC-9BCB34175352

P31

Q34973787-86B99609-8A38-488B-8C5B-123F8DABB16C

P356

Q34973787-F275E0DF-2E1B-43CA-A3A4-07169A155B36

P407

Q34973787-74227ABC-7597-4459-AD74-403B90593497

P433

Q34973787-7967F6C8-B6E9-42AE-9EBC-756961FB46D2

P478

Q34973787-A26C24C6-A880-4D7E-B545-99BD9F04A02C

P50

Q34973787-B8837298-CAB9-4918-BBEB-24429FFDB618

P577

Q34973787-146D2EEF-0B2C-4F69-9894-D9DC2ACEC7E1

P5875

Q34973787-3DB83896-6DC6-4A07-B90F-287CE807DEE2

P698

Q34973787-68C1D21D-A303-424A-809E-F8B16D78FBEB

P932

Q34973787-91940965-0318-4535-8D9C-06CF004BEE3C

P356

JOURNAL.PONE.0072301

P1433

P1476

Efficacy and safety of a lipos ...... 301L mice that model tauopathy

@en

P2093

Andrea Pfeifer

http://www.w3.org/2001/XMLSchema#string

Andreas Muhs

http://www.w3.org/2001/XMLSchema#string

Clara Theunis

http://www.w3.org/2001/XMLSchema#string

David T Hickman

http://www.w3.org/2001/XMLSchema#string

Dorin Mlaki Ndao

http://www.w3.org/2001/XMLSchema#string

Herman Devijver

http://www.w3.org/2001/XMLSchema#string

Maria Pihlgren

http://www.w3.org/2001/XMLSchema#string

María Pilar López-Deber

http://www.w3.org/2001/XMLSchema#string

Natalia Crespo-Biel

http://www.w3.org/2001/XMLSchema#string

Nathalie Chuard

http://www.w3.org/2001/XMLSchema#string

P2860

Recent developments in Alzheimer's disease therapeutics

A protein factor essential for microtubule assembly

Therapeutic approaches to Alzheimer's disease

Transmission and spreading of tauopathy in transgenic mouse brain

Neuropathological stageing of Alzheimer-related changes

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

Neurovascular regulation in the normal brain and in Alzheimer's disease

Age-related impairment of ultrasonic vocalization in Tau.P301L mice: possible implication for progressive language disorders.

Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice.

P304

e72301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0072301

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Fred van Leuven

P577

2013-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256102661

http://www.w3.org/2001/XMLSchema#string

P698

23977276

http://www.w3.org/2001/XMLSchema#string

P932

3747157

http://www.w3.org/2001/XMLSchema#string